Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | RET | P07949 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.62 |
| ▸ | ALPL | P05186 | 1/20 | 0.62 |
| ▸ | ALPI | P09923 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584530 | 0.83 | NPY5R (0.72) | NPC1RAB9ARETKDRNPY5R | |
| SCHEMBL7930564 | 0.82 | CSNK2A2 (0.65) | NPY5R | |
| SCHEMBL6562826 | 0.80 | NPC1 (1.00) | NPC1RAB9ARETKDRNPY5R | |
| SCHEMBL1663611 | 0.78 | NPC1 (0.89) | NPC1RAB9ARETKDRNPY5R | |
| SCHEMBL7932771 | 0.77 | MEN1 (0.55) | RETMAPT | |
| SCHEMBL6585868 | 0.77 | NPY5R (1.00) | NPC1RAB9ARETKDRNPY5R | |
| SCHEMBL4264906 | 0.75 | ALPL (0.78) | NPC1RAB9ARETKDRNPY5R | |
| SCHEMBL6566353 | 0.75 | NPC1 (1.00) | NPC1RAB9ANPY5RALPLALPI | |
| Hydrochloric Acid SCHEMBL20569132 | 0.75 | NPC1 (0.58) | NPC1RAB9ARETKDRNPY5R | |
| Hydrochloric Acid SCHEMBL20569135 | 0.75 | NPC1 (0.58) | NPC1RAB9ARETKDRNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | NPC1 428/4885RAB9A 3098/4885RET 4620/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | NPC1 4147/4885RAB9A 1619/4885RET 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.